Retractable Technologies, Inc. (NYSE:RVP)

Tuesday, March 31, 2020

Research

Retractable Technologies, Inc. (NYSE:RVP) ($1.71; $55.8M market cap), a company that designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States and internationally, announced its full year 2019 results via 10-K:

  • Full year 2019 sales of $41.7 million vs $33.2 million in the prior year
  • Full year 2019 EPS of $0.07 vs a loss of $0.06 in the prior year
  • Q4 2019 sales of $12.6 million vs $8.2 million in the prior year
  • EPS of $0.05 vs a loss of $0.01 in the prior year

On March 10, 2020, we published an in depth-article talking about the pros and cons of the RVP growth story.

The company has not issued a press release for its full year results yet. After filing its Q3 10-Q, the company issued a press release midway through the following day. So we will be on the lookout for a possible release sometime during the trading day today. 

In related news, yesterday we issued the following Tweet:

We are hoping management’s earnings release will provide more color on this possible contract modification, which explicitly mentions coronavirus in the description of the contract requirement. 

Please be aware that this contract is not new and is only a modification on the prior contract to specifically mention coronavirus. One of our premium members, Michael Liu, alerted us of this fact.

However, it appears that there have been no awards assigned to this contract yet.  You can view all modifications of the contract here

Now, with the arrival of the coronavirus, combined with the increasing need to protect healthcare personnel, we are curious to see if the government may actually start executing task orders against the contract.